Therapeutics

The EU Joint Clinical Assessment (#JCA), launched in 2025, is reshaping how oncology and #ATMP trials are designed and assessed across Europe. With 27 EU countries plus Norway, Switzerland, Ukraine and the UK now sharing...

Patient led organisations are shaping scientific and regulatory strategy in ultra rare diseases. Join our live panel as we bring together leaders whose work has contributed to gene therapies, accelerated approvals and ...

ADCs are transforming cancer treatment by combining targeted monoclonal antibodies with powerful cytotoxic agents. However their complexity poses bioanalytical challenges. Scientists face major challenges due to ADC he...

Regulatory change is coming to pediatric therapeutics. The EMA proposed a new MoA PIP requirement that could transform pediatric drug development and create an influx of more meaningful therapies. Learn from ICON exp...

ICON proudly supports International Childhood Cancer Day, reaffirming our commitment to advancing research and improving outcomes for children, survivors, and families affected by childhood cancer. In the past 5 years,...

ICON provides comprehensive cardiac safety monitoring supported by a team of cardiovascular electrophysiology specialists, board certified cardiologists, radiologists, and medical experts. We offer protocol consulting,...

Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe...

When patients lead, progress follows. Join ICON’s Centre for Rare Diseases for a special Rare Disease Day webinar exploring how patient and parent leaders are breaking barriers in ultra rare disease drug development. F...

Managing AI model biases in SaMD is no longer optional - it’s essential. As AI enabled medical devices accelerate through FDA authorisation, developers must ensure their models don’t unintentionally reinforce healthcare ...

Heart failure is one of the leading causes of hospitalisation among adults over 65. Cardiovascular outcome trials can be complex and costly. Find out how considering the human element of CVOTs, and building appropriate...

1 in 5 people will develop heart failure in their lifetime. ICON recognises the importance to raise global awareness of heart failure risk factors such as hypertension, obesity, diabetes and coronary heart disease. Dis...

ICON is proud to support Heart Failure Awareness Week. As a global leader in cardiovascular trials, we remain committed to raising awareness and advancing better, safer and more cost‑effective therapies for people living...